FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027138889> ?p ?o ?g. }

• W2027138889 endingPage "1185" @default.
• W2027138889 startingPage "1184" @default.
• W2027138889 abstract "Efavirenz (EFV) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) with a long half-life (approximately 45 h) allowing once-daily oral administration. As with the other NNRTI nevirapine, EFV is not only metabolized by cytochrome P450, family 3, subfamily A (CYP3A) isoenzymes, but also by CYP2B isoenzymes. EFV is highly bound to plasma proteins (99.5–99.7%) and is able to inhibit CYP3A4 and induce CYP2B6, CYP2C19 and CYP3A4 [1]. The recommended dosage of EFV is 600 mg every 24 h [2]. The therapeutic EFV plasma concentration range is 1.0–4.0 mg/l. Because of its metabolic route, not only negative drug–drug interactions, but also drug–herb interactions can occur. Here, we report virological failure in a 47-year-old HIV-infected patient who received antiretroviral therapy for 10 years. He had always been very drug-compliant, never missing a single dose. He was using EFV for 2 years in combination with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). At the end of 2007, a virological failure developed, and a K103N and M184V mutation in the reverse transcriptase gene was demonstrated. After directed questioning, the patient appeared to be using Ginkgo biloba for some months. No other comedication was used or discontinued in this timeframe. To explain the virological failure, plasma EFV concentration measurements were conducted on several plasma samples dating back 2 years. Concentrations of EFV decreased over time, coinciding with an increase in viral load (Table 1). From March 2008, the patient was successfully switched to alternative antiretroviral therapy.Table 1: HIV-1 RNA copies measured in plasma and efavirenz plasma concentrations.Ginkgo biloba is one of the most widely used herbal drugs in the world. It is commonly used because of its assumed beneficial effects on concentration, memory, dementia and depressive disorders. Ginkgo biloba extract (GBE) is made of Ginkgo leaves and is usually standardized to contain 24% flavonoids (quercetin, kaempferol and isorhamnetin), 6% terpenoids (ginkgolides A, B, C, J, M and bilobalide) and not more than 5 ppm organic acids (ginkolic acids and alkylphenols) [3]. Examining the properties of the constituents of GBE, the effects on cytochrome P450 metabolic routes can be anticipated. Research has shown that flavonoids can inhibit P-glycoprotein (P-gp) and CYP3A4 [3,4]. Terpenoids can induce P-gp, pregnane X receptor (PXR), multidrug-resistance 1 (MDR-1) and CYP3A4 [5], and organic acids can inhibit CYP2C9, CYP2C19, CYP2D6 and CYP3A4 [6]. Gingko biloba has been confirmed to interact with a number of drugs that are metabolized through cytochrome P450 isoenzymes (e.g. trazodone, warfarin, aspirin, ibuprofen, digoxin and omeprazole) [6]. In this case, we believe that the terpenoids have caused the negative pharmacokinetic interaction with EFV either by induction of CYP3A4 or P-gp. Not only strong inducers of CYP3A4, such as rifampicine, have often been described to lower NNRTI plasma levels leading to virological failure, but also induction of P-gp might have similar effects. P-gp is an ATP-dependant efflux transporter, which is known to transport various types of drugs out of the brain, out of the gonads, into the bile, into the urine and into the gut lumen. As EFV is metabolized by CYP3A4, it is likely that EFV also interacts with P-gp as has been observed for various cationic and lipophilic drugs. Indeed, Fellay et al. [7] have shown that single-nucleotide polymorphisms of P-gp have significant impacts on human plasma EFV levels. Therefore, the decrease of EFV plasma levels in this particular clinical case may also have been caused by induction of P-gp. Although the exact underlying mechanism remains unresolved, terpenoids in GBE may lower EFV plasma levels by the induction of CYP3A4 and P-gp. We conclude that an intake of GBE can decrease human plasma EFV levels, may result in virological failure and should be discouraged." @default.
• W2027138889 created "2016-06-24" @default.
• W2027138889 creator A5067277048 @default.
• W2027138889 creator A5073189722 @default.
• W2027138889 creator A5090138125 @default.
• W2027138889 date "2009-06-01" @default.
• W2027138889 modified "2023-10-14" @default.
• W2027138889 title "Interaction of Ginkgo biloba with efavirenz" @default.
• W2027138889 cites W1967735525 @default.
• W2027138889 cites W1985065867 @default.
• W2027138889 cites W2031862422 @default.
• W2027138889 cites W2074299694 @default.
• W2027138889 cites W2098342174 @default.
• W2027138889 cites W2098938825 @default.
• W2027138889 cites W2102013670 @default.
• W2027138889 doi "https://doi.org/10.1097/qad.0b013e32832c412b" @default.
• W2027138889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19451798" @default.
• W2027138889 hasPublicationYear "2009" @default.
• W2027138889 type Work @default.
• W2027138889 sameAs 2027138889 @default.
• W2027138889 citedByCount "34" @default.
• W2027138889 countsByYear W20271388892012 @default.
• W2027138889 countsByYear W20271388892013 @default.
• W2027138889 countsByYear W20271388892014 @default.
• W2027138889 countsByYear W20271388892015 @default.
• W2027138889 countsByYear W20271388892016 @default.
• W2027138889 countsByYear W20271388892017 @default.
• W2027138889 countsByYear W20271388892018 @default.
• W2027138889 countsByYear W20271388892019 @default.
• W2027138889 countsByYear W20271388892020 @default.
• W2027138889 countsByYear W20271388892021 @default.
• W2027138889 countsByYear W20271388892022 @default.
• W2027138889 crossrefType "journal-article" @default.
• W2027138889 hasAuthorship W2027138889A5067277048 @default.
• W2027138889 hasAuthorship W2027138889A5073189722 @default.
• W2027138889 hasAuthorship W2027138889A5090138125 @default.
• W2027138889 hasBestOaLocation W20271388891 @default.
• W2027138889 hasConcept C104317684 @default.
• W2027138889 hasConcept C109650736 @default.
• W2027138889 hasConcept C112705442 @default.
• W2027138889 hasConcept C126322002 @default.
• W2027138889 hasConcept C142462285 @default.
• W2027138889 hasConcept C156719811 @default.
• W2027138889 hasConcept C159047783 @default.
• W2027138889 hasConcept C185592680 @default.
• W2027138889 hasConcept C196013638 @default.
• W2027138889 hasConcept C2777351918 @default.
• W2027138889 hasConcept C2777447569 @default.
• W2027138889 hasConcept C2778998842 @default.
• W2027138889 hasConcept C2779130552 @default.
• W2027138889 hasConcept C2779778239 @default.
• W2027138889 hasConcept C2779889181 @default.
• W2027138889 hasConcept C2781432083 @default.
• W2027138889 hasConcept C2993143319 @default.
• W2027138889 hasConcept C3013748606 @default.
• W2027138889 hasConcept C50605568 @default.
• W2027138889 hasConcept C526171541 @default.
• W2027138889 hasConcept C55493867 @default.
• W2027138889 hasConcept C62231903 @default.
• W2027138889 hasConcept C67705224 @default.
• W2027138889 hasConcept C71924100 @default.
• W2027138889 hasConcept C86803240 @default.
• W2027138889 hasConcept C98274493 @default.
• W2027138889 hasConceptScore W2027138889C104317684 @default.
• W2027138889 hasConceptScore W2027138889C109650736 @default.
• W2027138889 hasConceptScore W2027138889C112705442 @default.
• W2027138889 hasConceptScore W2027138889C126322002 @default.
• W2027138889 hasConceptScore W2027138889C142462285 @default.
• W2027138889 hasConceptScore W2027138889C156719811 @default.
• W2027138889 hasConceptScore W2027138889C159047783 @default.
• W2027138889 hasConceptScore W2027138889C185592680 @default.
• W2027138889 hasConceptScore W2027138889C196013638 @default.
• W2027138889 hasConceptScore W2027138889C2777351918 @default.
• W2027138889 hasConceptScore W2027138889C2777447569 @default.
• W2027138889 hasConceptScore W2027138889C2778998842 @default.
• W2027138889 hasConceptScore W2027138889C2779130552 @default.
• W2027138889 hasConceptScore W2027138889C2779778239 @default.
• W2027138889 hasConceptScore W2027138889C2779889181 @default.
• W2027138889 hasConceptScore W2027138889C2781432083 @default.
• W2027138889 hasConceptScore W2027138889C2993143319 @default.
• W2027138889 hasConceptScore W2027138889C3013748606 @default.
• W2027138889 hasConceptScore W2027138889C50605568 @default.
• W2027138889 hasConceptScore W2027138889C526171541 @default.
• W2027138889 hasConceptScore W2027138889C55493867 @default.
• W2027138889 hasConceptScore W2027138889C62231903 @default.
• W2027138889 hasConceptScore W2027138889C67705224 @default.
• W2027138889 hasConceptScore W2027138889C71924100 @default.
• W2027138889 hasConceptScore W2027138889C86803240 @default.
• W2027138889 hasConceptScore W2027138889C98274493 @default.
• W2027138889 hasIssue "9" @default.
• W2027138889 hasLocation W20271388891 @default.
• W2027138889 hasLocation W20271388892 @default.
• W2027138889 hasLocation W20271388893 @default.
• W2027138889 hasOpenAccess W2027138889 @default.
• W2027138889 hasPrimaryLocation W20271388891 @default.
• W2027138889 hasRelatedWork W1975492163 @default.
• W2027138889 hasRelatedWork W1978037518 @default.
• W2027138889 hasRelatedWork W1987791325 @default.

• next